Dual targeting of Notch and Wnt/β‐catenin pathways: Potential approach in triple‐negative breast cancer treatment
The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
Despite the continuously growing repertoire of new and improved anti-cancer therapies, triple-negative breast cancer (TNBC) remains a clinical challenge to treat. In this sense, targeting signaling pathways such as Notch and Wnt/β-catenin have attracted growing attention. This work aimed at investigating the possible antitumor effects of IMR-1 as a Notch inhibitor, PRI-724 as a Wnt/β-catenin inhibitor, as well as their combination and to explore the possible crosstalk between Notch and Wnt/β-catenin signaling pathways in MDA-MB-231 TNBC cell line. Microculture tetrazolium test (MTT) was used to determine the drug growth inhibition (GI50), and the results were analyzed using CompuSyn 3.0.1 software. MDA-MB-231 cells were divided into four treatment groups including positive control, IMR-1-treated, PRI-724-treated, and combination-treated groups. Sandwich enzyme-linked immunosorbent assay (ELISA) was used for the determination of the protein levels of hairy and enhancer of split-1 (HES-1), Notch-1, β-catenin, cyclin-D1, and vascular endothelial growth factor (VEGF1). HES-1 gene expression was assessed by quantitative real-time polymerase chain reaction. Statistical analyses were performed using GraphPad Prism Software. The GI50 for IMR-1 and PRI-724 were 15.3 μM and 0.69 μM, respectively. Upon treatment of MDA-MB-231 cells with these drugs, HES-1 gene expression was up-regulated due to single and combined treatments. Moreover, the protein levels of cyclin-D1, VEGF1, HES-1, and Notch-1 were reduced, while those of active β-catenin and active caspase-3 were elevated. IMR-1/PRI-724 combination augmented IMR-1- and PRI-724-mediated effects on MDA-MB-231 cells by initiating apoptotic cell death. Further in vitro and in vivo studies are warranted to support our findings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other categories of Notch inhibitors, such as IMR‐1 and PRI‐724, have been found to be effective in inhibiting the Notch‐transcriptional complex in in vitro model of triple‐negative breast cancer [154].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [154]
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739 · cited 2×
“…and dose reduction indices To determine whether there is synergism, antagonism, or additive effect between IMR-1 and PRI-724, the combination index (CI) was determined as described by Chou 2010, where CI < 1 indicates synergism, =1 indicates additive effect, and > 1 indicates antagonistic effect.”
MethodTargeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors
Krishnamurthy, N., & Kurzrock, R. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.002 · Cited by 1,026
A small molecule inhibitor of β-catenin/cyclic AMP response element-binding protein transcription
Emami, K. H., Nguyen, C., Ma, H., Kim, D. H., Jeong, K. W., Eguchi, M., Moon, R. T., Teo, J.-L., Oh, S. W., Kim, H. Y., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404875101 · Cited by 874
A PCR primer bank for quantitative gene expression analysis
Wang, X. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng154 · Cited by 859
The Varied Roles of Notch in Cancer
Aster, J. C., Pear, W. S., & Blacklow, S. C. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100127 · Cited by 710
Cyclin D1, cancer progression, and opportunities in cancer treatment
Qie, S., & Diehl, J. A. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1475-3 · Cited by 657
Koussounadis, A., Langdon, S. P., Um, I. H., Harrison, D. J., & Smith, V. A. (2015) · Scientific Reports · doi:10.1038/srep10775 · Cited by 643
Riss, T., Moravec, R. A., Niles, A. L., Duellman, S. J., Benink, H. A., Worzella, T. J., & Minor, L. K. (2016) · Europe PMC (PubMed Central) · Cited by 619
Kovall, R. A., Gebelein, B., Sprinzak, D., & Kopan, R. (2017) · Developmental Cell · doi:10.1016/j.devcel.2017.04.001 · Cited by 407
Research works printed but not linked: 1
- Dang TP (2012) Notch, apoptosis and cancer BT - notch signaling in embryology and cancer. In: Reichrath J, Reichrath S (eds) Advances in experimental medicine and biology. Springer US, New York, pp 199–209
Cited by
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“Other categories of Notch inhibitors, such as IMR-1 and PRI-724, have been found to be effective in inhibiting the Notch-transcriptional complex in in vitro model of triple-negative breast cancer [154].”
BackgroundHashemi, M., Hasani, S., Hajimazdarany, S., Ghadyani, F., Olyaee, Y., Khodadadi, M., Ziyarani, M. F., Dehghanpour, A., Salehi, H., Kakavand, A., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123377 · Cited by 52
Roles of SIRT6 in kidney disease: a novel therapeutic target
Yang, X., Feng, J., Liang, W., Zhu, Z., Chen, Z., Hu, J., Yang, D., & Ding, G. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-04061-9 · Cited by 48
“Inhibiting the Wnt signaling pathway can restore the phenotype induced by the blockade of Notch signaling [108].”
BackgroundThe Notch Signaling Pathway Contributes to Angiogenesis and Tumor Immunity in Breast Cancer
Jiang, N., Hu, Y., Wang, M., Zhao, Z., & Li, M. (2022) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s376873 · Cited by 40
Wu, X., Lin, S.-G., Mao, Y.-W., Wu, J., Hu, C.-D., Lv, R., Zeng, H.-D., Zhang, M.-H., Lin, L., Ouyang, S.-S., et al. (2023) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2023.16 · Cited by 28
“56).”
Metadata
- Authors
- Nasser, F., Moussa, N., Helmy, M. W., & Haroun, M.
- Affiliations
- Alexandria University (EG)
- Damanhour University (EG)
- Corresponding author
- Moussa, Nermine
- Venue
- Naunyn-Schmiedeberg s Archives of Pharmacology
- Published
- 2020-10-14
- Volume
- 394
- Issue
- 3
- Pages
- 481-490
- ISSN
- 0028-1298 (ISSN-L)
- 1432-1912
- OpenAlex
- W3092285135
- Cited by
- 29
- References
- 40
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 2 · 2023: 5 · 2022: 4 · 2021: 2
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Naunyn-Schmiedeberg s Archives of Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- triple-negative breast cancer, Notch signaling, Wnt/β-catenin signaling, PRI-724, combination therapy, Hes1, Notch1, cyclin D1, apoptosis, MDA-MB-231 cells, signaling crosstalk
- MeSH terms
- Transcription Factor HES-1, Antineoplastic Agents, Drug Interactions, Humans, Pyrimidinones, Apoptosis, Bridged Bicyclo Compounds, Heterocyclic, Cyclin D1, Vascular Endothelial Growth Factor A, Cell Line, Tumor, Cell Proliferation, beta Catenin, Receptor, Notch1, Caspase 3, Thiazolidines, Wnt Signaling Pathway, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dual targeting of Notch and Wnt/β‐catenin pathways: Potential approach in triple‐negative breast cancer treatment. https://app.cochat.ai/papers/10.1007/s00210-020-01988-x
- The paper
- Nasser, F., Moussa, N., Helmy, M. W., & Haroun, M. (2021). Dual targeting of Notch and Wnt/β‐catenin pathways: Potential approach in triple‐negative breast cancer treatment. Naunyn-Schmiedeberg s Archives of Pharmacology. https://doi.org/10.1007/s00210-020-01988-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.